HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Uterine Neoplasms (Uterine Cancer)

Subscribe to New Research on Uterine Neoplasms

Tumors or cancer of the UTERUS.

Also Known As:

Uterine Cancer; Cancer of the Uterus; Neoplasms, Uterine; Neoplasms, Uterus; Uterus Cancer; Uterus Neoplasms; Cancer, Uterine; Cancer, Uterus; Cancers, Uterine; Cancers, Uterus; Neoplasm, Uterine; Neoplasm, Uterus; Uterine Cancers; Uterine Neoplasm; Uterus Cancers; Uterus Neoplasm; Cancer of Uterus

Networked: 969 relevant articles (26 outcomes, 73 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Diarrhea
2.	Endometriosis (Adenomyosis)
3.	Neoplasms (Cancer)
4.	Breast Neoplasms (Breast Cancer)
5.	Lung Neoplasms (Lung Cancer)

Experts

1.	Vogel, Victor G: 6 articles (12/2011 - 08/2002)
2.	Kapp, Daniel S: 6 articles (05/2011 - 06/2007)
3.	Lin, Szu-Ting: 5 articles (04/2015 - 10/2012)
4.	Chou, Hsiu-Chuan: 5 articles (04/2015 - 10/2012)
5.	Chan, Hong-Lin: 5 articles (04/2015 - 10/2012)
6.	Asselin, Eric: 5 articles (01/2010 - 09/2004)
7.	Chan, John K: 5 articles (11/2009 - 06/2007)
8.	Frumovitz, Michael: 4 articles (07/2015 - 09/2004)
9.	Ramirez, Pedro T: 4 articles (07/2015 - 09/2004)
10.	Coleman, Robert L: 4 articles (06/2015 - 05/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Uterine Neoplasms:

1.	Estrogens (Estrogen)FDA Link 12/30/2004 - "Numerous studies have suggested that the lifetime dose of unopposed estrogen is a significant risk factor for breast and uterine cancer. " 07/01/2014 - "Effective treatment is achieved primarily through activation of the estrogen receptor (ER)α with estrogens but is also associated with increased risk for breast and uterine cancer. " 08/01/2012 - "The incidence of corpus uteri (uterus) cancer is also strongly increased with exposure to estrogens. " 01/27/2011 - "Long-term use of estrogen supplements by women leads to an increased risk of breast and uterine cancers. " 02/01/2007 - "Novel estrogenic therapies are needed that ameliorate menopausal symptoms and have the bone-sparing effects of endogenous estrogens but do not promote breast or uterine cancer. "
2.	SeleniumIBA 02/01/2001 - "In this work, we report on a relationship between urinary selenium and the development of cervical uterine cancer. " 02/01/2001 - "Urinary selenium excretion in patients with cervical uterine cancer." 11/01/2010 - "We assessed whether adjuvant supplementation with selenium improves the selenium status and reduces side effects of patients treated by radiotherapy (RT) for cervical and uterine cancer. " 11/01/2014 - "In 2010, we reported that selenium (Se) supplementation during radiation therapy (RT) is effective for increasing blood Se levels in Se-deficient cervical and uterine cancer patients, and reduced the number of episodes and severity of RT-induced diarrhea. " 11/01/2010 - "Selenium supplementation during RT is effective in improving blood selenium status in selenium-deficient cervical and uterine cancer patients and reduces the number of episodes and severity of RT-induced diarrhea."
3.	Doxorubicin (Adriamycin)FDA LinkGeneric 05/05/2013 - "The current work shows that the redox 2D-DIGE-based proteomic strategy provides a rapid method to study the molecular mechanisms of doxorubicin-induced drug resistance in uterine cancer. " 04/01/2015 - "Our results provide potential diagnostic markers and therapeutic candidates for the treatment of doxorubicin-resistant uterine cancer. " 12/01/2014 - "To sum up, our results provide useful diagnostic markers and therapeutic candidates such as RCN1 for the treatment of doxorubicin-resistant uterine cancer. " 06/01/2014 - "Our results provide potential diagnostic markers and therapeutic candidates for treating doxorubicin-resistant uterine cancer. " 06/01/2014 - "Nuclear proteomics with XRCC3 knockdown to reveal the development of doxorubicin-resistant uterine cancer."
4.	Progesterone Receptors (Progesterone Receptor)IBA 08/01/1991 - "Uterine cancer cell lines included progesterone-receptor (PR)-positive AE7 and ECC1 and PR-negative HEC1A, HEC1B, AN3, and SKUT1B. " 08/01/2011 - "Progesterone receptor (PR) is a significant biomarker in diseases such as endometriosis and breast, ovarian, and uterine cancers that is associated with disease prognosis and therapeutic efficacy. " 11/16/2011 - "Progesterone receptor (PR) is strongly associated with disease prognosis and therapeutic efficacy in hormone-related diseases such as endometriosis and breast, ovarian, and uterine cancers. " 09/01/2001 - "[Hydrophobic DNA adducts in relationship to estrogen and progesterone receptors content in human uterine cancer]." 08/01/2015 - "Most uterine cancers, the most common gynecological malignancies in women in developed countries, are hormone-dependent endometrial adenocarcinomas (EACs) that express estrogen and progesterone receptors. "
5.	Tamoxifen FDA LinkGeneric 10/01/2009 - "We investigated the relationship between tamoxifen and cervical or uterine cancer in Iran, reviewing all the studies performed by the Vali-Asr Gynecology Oncology Clinic in Tehran. " 05/01/2006 - "The objective of this study was to determine the percentage of women who developed uterine cancer more than 12 months after discontinuing tamoxifen (past users) and to compare their clinical and pathologic features with those of women who developed uterine cancer while on tamoxifen therapy or within 12 months of stopping therapy (recent users). " 10/01/1999 - "Large clinical trials have pointed out that long-term tamoxifen therapy increases the risk of uterine cancers. " 11/01/2014 - "The uterine cancer risk was significantly increased in the pts receiving tamoxifen (adjusted HR = 2.79, P < 0.001), suggesting tamoxifen compliance. " 06/01/2014 - "Premenopausal women treated with tamoxifen have no known increased risk of uterine cancer and require no additional monitoring beyond routine gynecologic care. "
6.	HormonesIBA 01/01/2008 - "[Anti-steroid hormones for uterine cancer]." 12/01/1995 - " Decreased hormone doses in OCs have reduced most cardiovascular risk and protect against ovarian and uterine cancers. " 01/01/1993 - "Hormone therapy following breast and uterine cancer." 08/01/1990 - "Possible relationships between trends in exogenous hormone use and incidence rates of corpus uterine cancer are discussed." 08/01/1990 - "Recent trends in corpus uterine cancer incidence rates were explored using 1979-86 data from the Surveillance and End Results Program (SEER); recent trends in hospitalizations for corpus uterine cancer were explored using 1979-86 data from National Hospital Discharge Surveys (NHDS); and recent trends in exogenous hormone use were delineated using data from the 1980, 1981, and 1985 National Ambulatory Medical Care Surveys (NAMCS). "
7.	Sodium Selenite (Selenite)IBA 01/01/2009 - "Through this study, the significant benefits of sodium selenite supplementation with regards to selenium deficiency and radiotherapy induced diarrhea in patients with cervical and uterine cancer has been shown for the first time in a prospective randomized trial. "
8.	polylactic acid-polyglycolic acid copolymer (PLGA)IBA 06/01/2011 - "The authors of this study compare the cellular uptake and cytotoxicity of targeted and nontargeted doxorubicin loaded PLGA nanoparticle delivery systems in drug-resistant ovarian and uterine cancer cell lines, concluding that cellular uptake and cytotoxicity of doxorubicin can be improved by the proposed methods."
9.	Estrogen Receptor Modulators (Antiestrogen)IBA 07/10/1982 - "A new antiestrogen effective against uterine neoplasms]." 02/01/2007 - "The impact of 17beta-estradiol and antiestrogens on uterine cancer cells is poorly understood. " 03/01/1994 - "[Antiestrogen therapy of patients with uterine cancer]." 02/01/2007 - "Results demonstrated the importance of removing phenol red and the use of deprived serum when studying uterine cancer cells in relationship with 17beta-estradiol and antiestrogens. " 12/01/2006 - "We present the successful use of the antiestrogen fulvestrant in an endocrine therapy-naive patient with advanced uterine cancer. "
10.	CarbonIBA 01/01/2006 - "The effects of carbon ion irradiation revealed by excised perforated intestines as a late morbidity for uterine cancer treatment." 12/01/2015 - "Using 10-20 cases each of prostate, head and neck (HN), bone and soft tissue (BS), lung, liver, pancreas, and uterine neoplasms, the authors first used treatment plans for carbon-ion radiotherapy without nuclear interaction correction to derive uncorrected dose distributions. " 07/01/2006 - "Chromosome-type aberrations of peripheral lymphocytes of uterine cancer patients that received internal gamma- and external X-ray therapy or carbon beam therapy and of victims severely exposed to neutrons and gamma-rays in a criticality accident that occurred in Tokai-mura, Japan were analysed. " 01/01/2006 - "Perforated intestines as a late morbidity after carbon ion radiotherapy for uterine cancers were examined to reveal the biological characteristics of carbon ion for future applications for the treatment of gastrointestinal cancers. " 10/01/2004 - "On the other hand, carbon-ion beam therapy is giving good results in some selected carcinoma such as small cell lung cancer, prostate cancer, uterus cancer, and soft tissue/bone tumor. "

Therapies and Procedures

1.	Radiotherapy 05/01/2015 - "Para-aortic and Pelvic Radiotherapy, an Effective and Safe Treatment in Advanced-stage Uterine Cancer." 01/01/1983 - "[A cytological method in the evaluation of the efficacy of radiotherapy of uterine cancer]." 11/01/2015 - "Patients with a histological diagnosis of LNO gynecological cancer [uterine cervix (n = 14, 40 %), endometrial (n = 18, 51 %), ovarian (n = 3, 9 %)] who underwent surgery with radical intent and intraoperative radiotherapy (IORT), median dose 12.5 Gy) were considered eligible for participation in this study. " 03/01/2011 - "3D conformal postoperative radiotherapy with concomitant boost in uterine cancer: results of a phase I-II study (ADA-RT-1)." 07/01/1962 - "[Studies on the factors responsible for the results of radiotherapy of uterine cancer]."
2.	Lymph Node Excision (Lymph Node Dissection) 08/01/2007 - "Our data suggest that lymphadenectomy is associated with an improved survival in stage I grade 3 and more advanced endometrioid uterine cancers." 05/01/2011 - "The objective of this study was to assess whether para-aortic lymphadenectomy has therapeutic efficacy for patients with early-stage endometrioid uterine cancer who underwent systematic pelvic lymphadenectomy. " 12/01/2015 - "To evaluate the interaction between extent of lymph node dissection (LND) and overall survival (OS) in patients with various histologic types of uterine cancer. " 04/01/2013 - "Systemic lymphadenectomy is not warranted in stage Ia endometrioid uterine cancer." 04/01/2013 - "Among 244 endometrioid uterine cancer patients, 207 cases (84.8%) underwent systemic pelvic lymphadenectomy. "
3.	Hysterectomy 11/01/2015 - "The purpose of this study was to compare the costs and complications among women undergoing robotic and laparoscopic hysterectomy for uterine cancer. " 07/01/2015 - "For this Institutional Review Board (IRB)-approved study, we reviewed our prospectively-maintained uterine cancer database of 1,950 patients with EC International Federation of Gynecology and Obstetrics (FIGO) stages I-IV who underwent hysterectomy from 1/1988 through 12/2011. " 06/01/2011 - "Women aged 18 and older who underwent hysterectomy for uterine cancer were included in the study population. " 04/01/1990 - "The gravity of the pelvic lymphocysts after extended lymphadeno-colpo-hysterectomies for uterine cancers has been outlined in many studies and only a preventive strategy can reduce the morbidity, which is mainly of urinary order. " 01/01/1967 - "[Study of urographic results of lymphadeno-colpo-hysterectomy in the treatment of uterine cancer]."
4.	Hormone Replacement Therapy (Therapy, Hormone Replacement) 03/01/1999 - "This occurs provided that the diagnosis is not cancer of the uterus and there are no other serious contraindications to hormone replacement therapy. " 05/01/2005 - "Data from other relevant trials, including the most recent data on ovarian and uterine cancer risk and on gynecologic cancer patients, are also discussed to provide some guidelines on prescribing hormone replacement therapy in clinical practice, particularly in gynecologic cancer survivors." 05/01/2005 - "Hormone replacement therapy on ovarian and uterine cancer risk and cancer survivors: how shall we do no harm?" 03/01/1998 - "While breast and uterine cancer are valid concerns, selected high-risk women with and without established coronary disease should be counseled by an informed cardiologist to consider hormone replacement therapy." 05/01/2015 - "TWO CASE OF ATYPICAL ENDOMETRIAL HYPERPLASIA ASSOCIATED WITH "BIOIDENTICAL" HORMONE REPLACEMENT THERAPY: IGCS-0084 Uterine Cancer, including Sarcoma."
5.	Intrauterine Devices (Intrauterine Device) 04/01/2004 - "Although intrauterine device (IUD) usage has not been linked to uterine cancer and has even been considered protective against neoplasia, sporadic cases of IUD-associated uterine malignancies have been reported. " 07/01/1968 - "[Intrauterine devices and uterine cancer--statistical re-evaluation of Ishibama's data]." 09/01/2014 - "Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial."